NLTX vs. VSTM, KMDA, AVIR, ADCT, URGN, VNDA, NATR, RVNC, XERS, and SBTX
Should you be buying Neoleukin Therapeutics stock or one of its competitors? The main competitors of Neoleukin Therapeutics include Verastem (VSTM), Kamada (KMDA), Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), UroGen Pharma (URGN), Vanda Pharmaceuticals (VNDA), Nature's Sunshine Products (NATR), Revance Therapeutics (RVNC), Xeris Biopharma (XERS), and Silverback Therapeutics (SBTX). These companies are all part of the "pharmaceutical preparations" industry.
Neoleukin Therapeutics (NASDAQ:NLTX) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.
Neoleukin Therapeutics has higher earnings, but lower revenue than Verastem. Neoleukin Therapeutics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Neoleukin Therapeutics' return on equity of -37.22% beat Verastem's return on equity.
52.4% of Neoleukin Therapeutics shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 1.6% of Neoleukin Therapeutics shares are owned by insiders. Comparatively, 2.2% of Verastem shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Verastem received 547 more outperform votes than Neoleukin Therapeutics when rated by MarketBeat users. Likewise, 65.25% of users gave Verastem an outperform vote while only 45.87% of users gave Neoleukin Therapeutics an outperform vote.
Neoleukin Therapeutics has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500.
In the previous week, Verastem had 24 more articles in the media than Neoleukin Therapeutics. MarketBeat recorded 24 mentions for Verastem and 0 mentions for Neoleukin Therapeutics. Verastem's average media sentiment score of 0.15 beat Neoleukin Therapeutics' score of 0.00 indicating that Verastem is being referred to more favorably in the news media.
Verastem has a consensus price target of $26.50, suggesting a potential upside of 517.72%. Given Verastem's higher possible upside, analysts plainly believe Verastem is more favorable than Neoleukin Therapeutics.
Summary
Verastem beats Neoleukin Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Neoleukin Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NLTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Neoleukin Therapeutics Competitors List
Related Companies and Tools
